A Phase 4 interventional study of placebo and linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 145 sites in 17 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2018-07-03.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 8 that started in 2014, is one of 22 in phase 4, and was the 46th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 48th largest by enrollment of the 96 interventional ones that give a count, is one of 7 that started in 2014, is one of 9 in phase 4, and was the 91st registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy, safety, and tolerability of linagliptin 5 milligrams once a day compared to placebo as as add-on therapy for 24 weeks to stable basal insulin treatment in elderly patients, 60 years of age and older, with Type 2 Diabetes Mellitus and insufficient glycaemic control.Stable background therapy of metformin and/or alpha-glucosidase inhibitors is also allowed.
In addition, this trial will assess if linagliptin reduces the risk of hypoglycaemia when added to background basal insulin therapy. The treatment duration of this trial (24 weeks) will enable assessment of the clinically relevant endpoint of a decrease in glycosylated Haemoglobin, a well-accepted measurement of chronic glycaemic control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient to receive a tablet of linagliptin 5 mg each day
Drug: linagliptin
patient to receive a tablet of placebo matching linagliptin 5 mg
Drug: placebo
placebo matching linagliptin 5 mg
5 mg once a day
Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.
This outcome has measured difference between HbA1c values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication. HbA1c is a form of hemoglobin, a blood pigment that carries oxygen, which is bound to glucose. The term HbA1c also refers to glycated hemoglobin. High levels of HbA1c (Normal range is less than 6%) indicate poorer control of diabetes than level in normal range.
Time frame: Baseline and Week 24
Percentage of Patients Experiencing at Least One Hypoglycaemia Accompanied by a Prespecified Glucose Value.
Hypoglycaemia accompanied by a prespecified glucose value is defined as any investigator reported hypoglycaemia (event or AE) with a reported blood glucose level of less than 54 milligram/deciLitre (3.0 millimole/Litre) or any investigator reported symptomatic hypoglycaemic AE with a reported blood glucose level of less or equal 70 milligram/deciLitre (3.9millimole/Litre) or any severe hypoglycaemic AE. Severe hypoglycaemia is an event that requires the assistance of another person to actively administer carbohydrates or glucagon because the patient is unable to take the substance on his or her own. The confidence intervals mentioned in measure of dispersion are exact 95% confidence interval by Clopper and Pearson. The percentage of patients with at least one hypoglycaemia accompanied by a glucose value less than 54mg/dL alone has also represented separately according American Diabetes Association definition of clinically significant hypoglycaemia.
Time frame: 24 weeks
Percentage of Patients With HbA1c<8.0%
This is the percentage of patients with HbA1c on treatment \<8.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Time frame: 24 weeks
Percentage of Patients With HbA1c on Treatment <7.0%
This is the percentage of patients with HbA1c on treatment \<7.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Time frame: 24 weeks
Percentage of Patients With HbA1c Lowering by at Least 0.5%.
The percentage of patients who attained lowering of HbA1c by ≥0.5% from baseline after 24 weeks of treatment were analysed. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
Time frame: 24 weeks
Change From Baseline in Fasting Plasma Glucose (FPG)
This outcome has measured difference between FPG values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication
Time frame: Baseline and Week 24
This was randomised, double blinded, placebo controlled, parallel study. Total 525 patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control were screened. 302 patients were randomised into two groups. The trial was extended to 52 weeks for Japanese patients. 102 patients were identified and observed for the extended period.
| Milestone | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) | Placebo (Up to 52 Weeks) | Linagliptin 5 Milligram (Up to 52 Weeks) |
|---|---|---|---|---|
| Started | 151 | 151 | 0 | 0 |
| Completed | 136 | 143 | 0 | 0 |
| Not completed | 15 | 8 | 0 | 0 |
| Withdrew: Adverse event | 6 | 6 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 0 |
| Withdrew: Other than specified | 1 | 0 | 0 | 0 |
| Milestone | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) | Placebo (Up to 52 Weeks) | Linagliptin 5 Milligram (Up to 52 Weeks) |
|---|---|---|---|---|
| Started | 0 | 0 | 50 | 52 |
| Completed | 0 | 0 | 42 | 45 |
| Not completed | 0 | 0 | 8 | 7 |
| Withdrew: Adverse event | 0 | 0 | 6 | 7 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
This outcome has measured difference between HbA1c values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication. HbA1c is a form of hemoglobin, a blood pigment that carries oxygen, which is bound to glucose. The term HbA1c also refers to glycated hemoglobin. High levels of HbA1c (Normal range is less than 6%) indicate poorer control of diabetes than level in normal range.
| Percentage (%) of HbA1c | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment. | -0.38 ± 0.07 | -1.01 ± 0.06 |
Hypoglycaemia accompanied by a prespecified glucose value is defined as any investigator reported hypoglycaemia (event or AE) with a reported blood glucose level of less than 54 milligram/deciLitre (3.0 millimole/Litre) or any investigator reported symptomatic hypoglycaemic AE with a reported blood glucose level of less or equal 70 milligram/deciLitre (3.9millimole/Litre) or any severe hypoglycaemic AE. Severe hypoglycaemia is an event that requires the assistance of another person to actively administer carbohydrates or glucagon because the patient is unable to take the substance on his or her own. The confidence intervals mentioned in measure of dispersion are exact 95% confidence interval by Clopper and Pearson. The percentage of patients with at least one hypoglycaemia accompanied by a glucose value less than 54mg/dL alone has also represented separately according American Diabetes Association definition of clinically significant hypoglycaemia.
| Percentage of patients (%) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) |
|---|---|---|
| Prespecified glucose value | 23.8 (17.2 to 31.5) | 30.9 (23.6 to 39.0) |
| Glucose value <54 mg/dL | 15.0 (9.6 to 21.8) | 16.8 (11.2 to 23.8) |
This is the percentage of patients with HbA1c on treatment \<8.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
| Percentage of patients (%) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) |
|---|---|---|
| Percentage of Patients With HbA1c<8.0% | 40.2 (29.9 to 51.3) | 70.1 (59.4 to 79.5) |
This is the percentage of patients with HbA1c on treatment \<7.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
| Percentage of Patients (%) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) |
|---|---|---|
| Percentage of Patients With HbA1c on Treatment <7.0% | 14.6 (9.3 to 21.4) | 37.8 (29.8 to 46.2) |
The percentage of patients who attained lowering of HbA1c by ≥0.5% from baseline after 24 weeks of treatment were analysed. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.
| Percentage of patients (%) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) |
|---|---|---|
| Percentage of Patients With HbA1c Lowering by at Least 0.5%. | 37.4 (29.6 to 45.8) | 69.1 (61.0 to 76.4) |
This outcome has measured difference between FPG values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication
| milligram/decilitre | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | 0.2 ± 3.6 | -11.3 ± 3.3 |
Collected over The adverse events were reported by overall population from first drug administration up to treatment period of 24 weeks, until 7 days after last drug administration. The adverse events were reported by Japanese population from first drug administration up to treatment period of 52 weeks, until 7 days after last drug administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Up to 24 Weeks) | 0/151 (0%) | 21/151 (13.9%) | 58/151 (38.4%) |
| Linagliptin 5 mg (Up to 24 Weeks) | 2/151 (1.3%) | 19/151 (12.6%) | 72/151 (47.7%) |
| Placebo (Up to 52 Weeks) | 0/50 (0%) | 7/50 (14%) | 19/50 (38%) |
| Linagliptin 5mg (Up to 52 Weeks) | 0/52 (0%) | 13/52 (25%) | 37/52 (71.2%) |
| Event | Placebo (Up to 24 Weeks) | Linagliptin 5 mg (Up to 24 Weeks) | Placebo (Up to 52 Weeks) | Linagliptin 5mg (Up to 52 Weeks) |
|---|---|---|---|---|
| CataractEye disorders | 0/151 | 1/151 | 0/50 | 2/52 |
| Diabetic retinopathyEye disorders | 0/151 | 2/151 | 0/50 | 2/52 |
| CholecystitisHepatobiliary disorders | 1/151 | 0/151 | 1/50 | 0/52 |
| CholelithiasisHepatobiliary disorders | 1/151 | 0/151 | 1/50 | 0/52 |
| PneumoniaInfections and infestations | 1/151 | 0/151 | 1/50 | 0/52 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/151 | 0/151 | 1/50 | 0/52 |
| Rib fractureInjury, poisoning and procedural complications | 0/151 | 0/151 | 1/50 | 0/52 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/151 | 0/151 | 1/50 | 0/52 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/151 | 1/151 | 1/50 | 1/52 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/151 | 2/151 | 1/50 | 0/52 |
| Event | Placebo (Up to 24 Weeks) | Linagliptin 5 mg (Up to 24 Weeks) | Placebo (Up to 52 Weeks) | Linagliptin 5mg (Up to 52 Weeks) |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 38/151 | 51/151 | 14/50 | 20/52 |
| Viral upper respiratory tract infectionInfections and infestations | 8/151 | 11/151 | 3/50 | 11/52 |
| BronchitisInfections and infestations | 4/151 | 7/151 | 0/50 | 5/52 |
| Urinary tract infectionInfections and infestations | 9/151 | 10/151 | 1/50 | 1/52 |
| Back painMusculoskeletal and connective tissue disorders | 6/151 | 5/151 | 3/50 | 2/52 |
| ConstipationGastrointestinal disorders | 1/151 | 2/151 | 0/50 | 3/52 |
| Large intestine polypGastrointestinal disorders | 0/151 | 2/151 | 0/50 | 3/52 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 1/151 | 3/151 | 0/50 | 3/52 |
Treated set (TS): It includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.
| Age, Continuous(Years) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) | Total |
|---|---|---|---|
| Mean | 72.5 ± 5.6 | 72.3 ± 5.1 | 72.4 ± 5.4 |
| Sex: Female, Male(Participants) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) | Total |
|---|---|---|---|
| Female | 60 | 59 | 119 |
| Male | 91 | 92 | 183 |
| Ethnicity (NIH/OMB)(Participants) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 15 | 34 |
| Not Hispanic or Latino | 132 | 136 | 268 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 4 | 11 |
| Asian | 52 | 52 | 104 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 10 | 8 | 18 |
| White | 81 | 84 | 165 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Hemoglobin A1c (HbA1c) at baseline(Percentage of HbA1c (%)) | Placebo (Up to 24 Weeks) | Linagliptin 5 Milligram (Up to 24 Weeks) | Total |
|---|---|---|---|
| Mean | 8.1 ± 0.7 | 8.2 ± 0.8 | 8.2 ± 0.8 |
Showing the first 100 of 145 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Apr 2017, 30 months.
Results were first posted in Jul 2018, 1 year 2 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 30 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin